Skip to content

Should Australian Psychology Consider Enhancing Psychotherapeutic Interventions with Psychedelic Drugs? A Call for Research

Stephen Bright, Martin L Williams

Australian psychologist December 1, 2018 DOI: 10.1111/ap.12345 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Key findings Argues that international evidence is mounting that psychedelic-assisted psychotherapy can enhance psychotherapeutic outcomes and may be effective for some treatment-refractory mental illnesses, with 3,4-methylenedioxymethamphetamine-assisted psychotherapy entering Phase III trials, and proposes that Australian psychologists engage in formal psychedelic research given the absence of such a program in Australia.

Abstract

International research is increasingly demonstrating that psychedelic‐assisted psychotherapy can enhance psychotherapeutic outcomes and be effective for some treatment‐refractory mental illnesses; however, there is an absence of any such research in Australia. A review of psychedelic science has been conducted with a focus on psychedelic‐assisted psychotherapy to highlight the degree to which such research is occurring overseas. While some studies are in their early stages and the methods are undergoing continuous refinement, other areas are more advanced, including 3,4‐methylenedioxymethamphetamine‐assisted psychotherapy which is commencing Phase III clinical trials. In all cases, evidence is mounting that psychedelics hold promise in enhancing psychotherapy and furthering current understandings of the brain. Given that there is no psychedelic science program in Australia, we propose that Australian psychologists join the global biomedical community and engage in formal psychedelic research.

Citations in the library

Cited by 10

and 5 more in the library

Cites 36

and 31 more in the library

Explore topics